A recent study published in Pediatric and Developmental Pathology explored the molecular characteristics of pediatric fusion-negative rhabdomyosarcoma by analyzing tumors from 12 patients aged 6 days to 15 years. Utilizing targeted RNA sequencing, the researchers achieved high sensitivity and specificity in detecting genetic alterations that correlate with the tumors' clinicopathologic features. Notably, mutations in the RAS pathway and FGFR4 were found, along with DICER1 mutations in certain cases. This comprehensive analysis enhances understanding of rhabdomyosarcoma, potentially leading to improved treatments.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
